Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06484686 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine

StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less
    • Primary completion date: Sep 2026 to Dec 2028
    • Study sites: 0 to 1
    • Study completion date: Sep 2028 to Dec 2031
    • Start date changed from estimate of Sep 2024 to Sep 16, 2024
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This an open-label phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 6 and 10 years after booster dose.
Trial Details
NCT Number NCT06484686
Lead Sponsor Sinovac (Dalian) Vaccine Technology Co., Ltd.
Conditions
(from sponsor)		 Varicella
Related terms Chickenpox
Enrollment 414 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov